Abstract
Just hours before a deadline imposed by the UK Takeover Panel, AbbVie has finally got the backing of Shire’s Board of Directors for its sweetened £32 B (US$54.8 B) cash and share offer for the company. The deal, the largest tax inversion in the life sciences sector to date, will lower the company’s effective tax rate to approximately 13% from 22% at present. It will also bring in a diversified portfolio, including Vyvanse® (lisdexamfetamine dimesylate) for attention deficit hyperactivity disorder and rare disease therapies such as Elaprase® (idursulphase) and Replagal® (agalsidase alpha), thus reducing AbbVie’s reliance on Humira® (adalimumab).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
